Skip to main content
Clinical Trials/NCT05037214
NCT05037214
Completed
N/A

Measure of Stress After the First Wave of Covid 19 Within Hospital Workers

University Hospital, Montpellier1 site in 1 country779 target enrollmentJune 1, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
COVID 19
Sponsor
University Hospital, Montpellier
Enrollment
779
Locations
1
Primary Endpoint
Sleep
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

As of December 2019, the global pandemic of COVID-19 has spread rapidly throughout the world, putting healthcare staff at the frontline.

In this context, several factors leading to the appearance of psychiatric symptoms have emerged : work overload, fear of being infected or of infecting, exhaustion... (The Lancet, 2020)

Indeed, post-traumatic stress disorder (PTSD), depressive symptoms, anxiety symptoms, insomnia and increased stress have been reported (Rossi et al., 2020).

Furthermore, the increased anxiety and depression symptoms and stress associated with the COVID-19 pandemic may increase the risk of suicide in this already high-risk population. For example, suicidal ideation has been reported in up to 5% of healthcare workers in the United States (Young et al., 2021).

It is therefore essential to evaluate the incidence of psychiatric disorders (e.g. PTSD, depression, suicide) and their associated risk factors among the hospital staff.

To do so, Montpellier University Hospital healthcare staff was asked their mental state during the first wave of COVID-19.

Registry
clinicaltrials.gov
Start Date
June 1, 2020
End Date
June 30, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Sleep

Time Frame: day 1

sleep quality assessed with the Insomnia Severity Index (ISI) : higher score indicates higher insomnia level (min : 0; max : 28)

Anxiety symptoms

Time Frame: day 1

anxiety level assessed with the Generalized Anxiety Disorder questionnaire (GAD-7) : higher score indicates higher anxiety (min : 0; max : 21)

Depression symptoms

Time Frame: day 1

depression symptomatoloy assessed with the Patient Health Questionnaire (PHQ-9) : higher score indicates higher depression level (min : 0; max : 27)

Secondary Outcomes

  • Physical pain(day 1)
  • Burnout symptoms(day 1)
  • Post traumatic stress disorder(day 1)

Study Sites (1)

Loading locations...

Similar Trials